Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848942 | 0.88 | PDE4B (0.43) | KDM4ESMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL5847163 | 0.81 | KMT2A (0.49) | KDM4ESMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL6889608 | 0.76 | CMA1 (0.38) | SMN1; SMN2CMA1RAB9ANPC1ALDH1A1 | |
| SCHEMBL5847822 | 0.75 | LPAR3 (0.43) | SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL28832049 | 0.73 | KDM4E (0.59) | KDM4ESMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL260808 | 0.69 | KDM4E (0.50) | KDM4ESMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL6980198 | 0.68 | ELANE (0.55) | KDM4ESMN1; SMN2RAB9AALDH1A1KMT2A | |
| SCHEMBL7231594 | 0.68 | ALDH1A1 (0.46) | KDM4ESMN1; SMN2RAB9AALDH1A1KMT2A | |
| SCHEMBL7366632 | 0.67 | ADORA2B (0.43) | KDM4ECMA1LMNAMAPTHTT | |
| SCHEMBL7232479 | 0.67 | TNF (0.46) | KDM4ESMN1; SMN2RAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015230-B1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6458952-B1 | ENZYME INHIBITORS FOR SERINE METHODS FOR PREVENTING AND TREATING THROMBOTIC CONDITIONS SUCH AS CORONARY ARTERY AND CEREBROVASCULAR DISEASE WITH COMPOUNDS THAT INHIBIT SERINE PROTEASES OF THE COAGULATION CASCADE. | PHARMACIA CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1178971-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | TFPI, PLAT, PLAU | KDM4E 2451/4885SMN1; SMN2 3331/4885CMA1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.